Ocular Therapeutix (OCUL) Accumulated Expenses (2013 - 2026)

Ocular Therapeutix has reported Accumulated Expenses for 14 years, with the latest figure at $36.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 17.4% year-over-year to $36.5 million; the trailing twelve-month figure through Mar 2026 stood at $36.5 million (up 17.4% YoY), and the FY2025 full-year result was $43.8 million, up 207.14% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $36.5 million, down from $43.8 million in the prior quarter.
• The five-year high for Accumulated Expenses was $43.8 million in Q4 2025, with the low at $5.4 million in Q1 2024.
• Average Accumulated Expenses over 5 years is $19.3 million, with a median of $17.6 million recorded in 2022.
• Year-over-year, Accumulated Expenses plunged 75.6% in 2024 and soared 479.09% in 2025.
• Tracing OCUL's Accumulated Expenses over 5 years: stood at $7.5 million in 2022, then rose by 8.62% to $8.2 million in 2023, then surged by 74.99% to $14.3 million in 2024, then jumped by 207.14% to $43.8 million in 2025, then retreated by 16.76% to $36.5 million in 2026.
• The last three Accumulated Expenses figures came in at $36.5 million (Q1 2026), $43.8 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.

Peer Comparison